See the DrugPatentWatch profile for Tremfya
Can you restart or “retreat” with Tremfya (guselkumab) if you have a history of tuberculosis?
Tremfya (guselkumab) is an immunosuppressive biologic used for plaque psoriasis. If someone has a history of tuberculosis (TB), clinicians typically focus on whether the patient already had adequate TB treatment and whether TB risk is low or active.
In patients with TB exposure/history, treatment decisions usually hinge on two questions:
1) Is there any evidence of active TB right now?
2) Has the patient completed appropriate treatment for latent TB (or otherwise addressed TB risk)?
Your question suggests TB history and that you “treated” it, then later need to “retreat” (restart again). In practice, retreatment would only be considered after reassessing TB status (active vs latent) and reviewing prior TB regimens and outcomes.
What usually happens before Tremfya is started or continued in patients with TB history?
Before starting biologic therapy like Tremfya, clinicians generally screen for TB risk (for example, medical history, symptoms, and TB tests). If TB is identified or strongly suspected, the patient is treated first and then biologic therapy is considered once treatment is underway or completed, according to clinical guidance and infectious disease input.
If you already took TB treatment, the next step is usually documentation of:
- the diagnosis (latent TB vs active TB),
- the regimen used,
- how long you took it,
- and whether TB treatment was completed successfully.
If that information isn’t clear, doctors often repeat evaluation before re-starting or continuing the biologic.
If the TB was treated, why might a doctor still stop Tremfya or require “retreatment”?
Even after prior treatment, a clinician may require additional steps if:
- symptoms suggest possible reactivation,
- TB test results have changed,
- imaging or labs raise concern,
- or the earlier TB treatment course was incomplete or uncertain.
Reactivation risk and retreatment decisions also depend on factors like immune status, TB strain risk, and how long it has been since treatment.
What symptoms should trigger urgent evaluation while on or considering Tremfya?
If TB is a concern while on Tremfya (or when planning to restart), any TB-like symptoms should be checked urgently. Common red flags include persistent cough, coughing up blood, fever, night sweats, and unexplained weight loss. If you have any of these, you should contact your prescribing doctor immediately.
Can you stay on Tremfya during TB treatment, or do you pause it?
That depends on whether TB is active or latent, the severity, and the urgency of psoriasis control. With active TB, immunosuppressive biologics are typically held until the infection is addressed under TB/infectious disease care. For latent TB, the approach may differ depending on timing and risk; clinicians often coordinate a plan that balances psoriasis control and TB safety.
Because your wording includes “treated” and “need to retreat,” this sounds like a case where timing and prior treatment adequacy matter a lot. The safest next step is clinician confirmation of whether the prior TB was latent or active and whether the full course was completed.
Which TB documentation should you bring to your dermatologist/infectious disease doctor?
Bring or request:
- your TB diagnosis type (latent vs active),
- the exact medication names and dates,
- total duration and whether it was completed,
- baseline and follow-up test results if available,
- and any chest X-ray/CT findings.
That lets the doctor decide whether re-starting (or continuing) Tremfya is appropriate and whether additional TB treatment is needed.
Where does DrugPatentWatch.com fit in for Tremfya and TB concerns?
DrugPatentWatch.com can help if your goal is to track Tremfya’s patent/exclusivity status, but it does not typically provide patient-level TB management guidance. For TB safety decisions, you’ll want your prescriber’s TB screening protocol and infectious disease input. (If you want, tell me whether you’re asking about medical safety or treatment/patent timing and I’ll tailor the answer.)
Quick clarifying questions (so I can answer your situation precisely)
1) Was the TB you treated latent TB or active TB?
2) What treatment did you take (names) and for how many months?
3) Are you currently on Tremfya or planning to restart it?
4) When you say “need to retreat,” do you mean another TB medication course, or restarting Tremfya after stopping?
Sources
- [1] https://www.drugpatentwatch.com/